Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MYOKARDIA, INC.

(MYOK)
SummaryChartsNewsRatingsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bristol Myers sees up to $25 billion a year of new revenue from current drug pipeline

01/11/2021 | 08:06am EDT

NEW YORK (Reuters) - Bristol Myers Squibb said on Monday that its current drug pipeline has the ability to replace up to $25 billion a year in lost revenue from patent expirations by the end of the decade.

According to a presentation for JP Morgan's annual healthcare conference, the company said anemia drug Reblozyl, as well as experimental heart drug mavacamten, psoriasis drug deucravacitinib and its cancer cell therapy franchise could each be responsible for more than $4 billion a year in revenue. Other drugs in the pipeline would make up the rest.

Reblozyl and one of the cancer cell therapies were picked up in the company's $74 billion acquisition of Celgene last year. It acquired mavacamten this year in a $13 billion purchase of MyoKardia Inc.

"This really does speak to the importance of being able to not only source innovation internally, but having the financial wherewithal to be able to source innovation successfully externally," Chief Commercial Officer Chris Boerner said in an interview. "That flexibility financially - and being willing to move quickly to become a partner of choice - is going to serve us well as we continue to navigate the loss of exclusivity for products in the future."

Bristol Myers is expected to pull in more than $27 billion in sales - around two-thirds of its revenue this year - from its top three drugs, cancer drugs Revlimid and Opdivo and blood thinner Eliquis.

Revlimid will lose some of its U.S. patent exclusivity in 2022 and Eliquis could lose U.S. exclusivity after 2026. Opdivo's patents also begin to expire later this decade.

Shares of Bristol Myers closed at $62.49 on the New York Stock Exchange on Friday.

(Reporting by Michael Erman; editing by Diane Craft)


ę Reuters 2021
All news about MYOKARDIA, INC.
02/23Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of ..
AQ
02/04BRISTOL MYERS SQUIBB : Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo
DJ
01/11Bristol Myers sees up to $25 billion a year of new revenue from current drug pipeline
RE
01/08Avidity Biosciences, Inc. Enters into A Research Collaboration with MyoKardia
CI
2020BRISTOL MYERS SQUIBB : Completes Acquisition of MyoKardia, Strengthening Company's leading..
AQ
2020MyoKardia, Inc. Announces Board Changes
CI
2020MYOKARDIA, INC. : Termination of a Material Definitive Agreement, Completion of Acquisitio..
AQ
2020MYOKARDIA, INC.(NASDAQGM : MYOK) dropped from Russell 3000 Index
CI
2020MYOKARDIA, INC.(NASDAQGM : MYOK) dropped from Russell 2500 Index
CI
2020MYOKARDIA, INC.(NASDAQGM : MYOK) dropped from Russell 2000 Index
CI
More news
Analyst Recommendations on MYOKARDIA, INC.
More recommendations
Chart MYOKARDIA, INC.
Duration : Period :
MyoKardia, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Anastasios E. Gianakakos Chief Executive Officer
Elizabeth Mily President & Director
Robert Scott McDowell Chief Scientific Officer
Jay Edelberg Senior Vice President-Clinical Development
Jeffrey Galik Treasurer, Director & Vice President
Sector and Competitors
1st jan.Capi. (M$)
MYOKARDIA, INC.0.00%11 993
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992